Subcutaneous Ocrelizumab Reduces Hospital Costs in Multiple Sclerosis Budget Model
A dynamic health economic model demonstrates that introducing subcutaneous ocrelizumab for relapsing multiple sclerosis could save Italian hospital centers approximately ...








